AAA
XBI icon

Affinity Asset Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Affinity Asset Advisors’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-37,550
Closed -$3.48M – 108
2024
Q2 		$3.48M Buy
+37,550
New +$3.37M 0.4% 53

Other funds holding XBI

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Affinity Asset Advisors's XBI Position: Q3 2024 in Review

Affinity Asset Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2024, closing a stake of 37,550 shares — an estimated $3.48M sold.

Affinity Asset Advisors first reported a position in XBI in Q2 2024 and held it in 1 quarter. The position peaked at $3.48M in Q2 2024. 769 funds tracked by Wall St. Rank hold XBI as of Q3 2024.

  • Affinity Asset Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2024 after selling out during the quarter.
  • Affinity Asset Advisors sold 37,550 State Street SPDR S&P Biotech ETF shares in Q3 2024, an estimated $3.48M.
  • Affinity Asset Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q2 2024 and held it in 1 quarter.
  • Affinity Asset Advisors's State Street SPDR S&P Biotech ETF position peaked at $3.48M in Q2 2024.
  • 769 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2024.

Based on Affinity Asset Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.